Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Aneuploidy, TP53 mutation, and amplification of MYC correlate with increased intratumor heterogeneity and poor prognosis of breast cancer patients.

Oltmann J, Heselmeyer-Haddad K, Hernandez LS, Meyer R, Torres I, Hu Y, Doberstein N, Killian JK, Petersen D, Zhu YJ, Edelman DC, Meltzer PS, Schwartz R, Gertz EM, Schäffer AA, Auer G, Habermann JK, Ried T.

Genes Chromosomes Cancer. 2018 Apr;57(4):165-175. doi: 10.1002/gcc.22515. Epub 2018 Jan 9.

2.

FISH cytogenetics and prognosis in breast and non-small cell lung cancers.

Massoner A, Augustin F, Duba HC, Zojer N, Fiegl M.

Cytometry B Clin Cytom. 2004 Nov;62(1):52-6.

3.

MYC gene amplification is often acquired in lethal distant breast cancer metastases of unamplified primary tumors.

Singhi AD, Cimino-Mathews A, Jenkins RB, Lan F, Fink SR, Nassar H, Vang R, Fetting JH, Hicks J, Sukumar S, De Marzo AM, Argani P.

Mod Pathol. 2012 Mar;25(3):378-87. doi: 10.1038/modpathol.2011.171. Epub 2011 Nov 4.

4.

Detection of HER-2/neu, c-myc amplification and p53 inactivation by FISH in Egyptian patients with breast cancer.

Ismail MF, Aly MS, Khaled HM, Mohamed HM.

Ger Med Sci. 2009 May 6;7:Doc03. doi: 10.3205/000062.

5.

Amplification of c-myc by fluorescence in situ hybridization in a population-based breast cancer tissue array.

Rummukainen JK, Salminen T, Lundin J, Kytölä S, Joensuu H, Isola JJ.

Mod Pathol. 2001 Oct;14(10):1030-5.

6.

Common patterns of genetic evolution in human solid tumors.

Shackney SE, Shankey TV.

Cytometry. 1997 Sep 1;29(1):1-27. Review.

PMID:
9298807
7.
8.

Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients.

Liang DH, Ensor JE, Liu ZB, Patel A, Patel TA, Chang JC, Rodriguez AA.

Breast Cancer Res Treat. 2016 Jan;155(1):139-49. doi: 10.1007/s10549-015-3635-5. Epub 2015 Dec 14.

PMID:
26667234
9.

MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency.

Ren J, Jin F, Yu Z, Zhao L, Wang L, Bai X, Zhao H, Yao W, Mi X, Wang E, Olopade OI, Wei M.

Tumour Biol. 2013 Dec;34(6):3945-58. doi: 10.1007/s13277-013-0983-9. Epub 2013 Jul 17.

PMID:
23860775
10.

Evaluation of MYC and chromosome 8 copy number in breast carcinoma by interphase cytogenetics.

Visscher DW, Wallis T, Awussah S, Mohamed A, Crissman JD.

Genes Chromosomes Cancer. 1997 Jan;18(1):1-7.

PMID:
8993975
11.

DNA copy number aberrations associated with aneuploidy and chromosomal instability in breast cancers.

Kawauchi S, Furuya T, Ikemoto K, Nakao M, Yamamoto S, Oka M, Sasaki K.

Oncol Rep. 2010 Oct;24(4):875-83.

PMID:
20811667
12.

Chromosomal 20q gain in the DNA diploid component of aneuploid colorectal carcinomas.

De Angelis PM, Stokke T, Beigi M, Flatberg G, Enger M, Haug K, Aass HC, Schjølberg A, Andresen PA, Ariansen S, Bø AS, Mjåland O, Clausen OP.

Int J Cancer. 2007 Jun 15;120(12):2734-8.

13.

Analysis of genetic alterations associated with DNA diploidy, aneuploidy and multiploidy in gastric cancers.

Sugai T, Habano W, Jiao YF, Suzuki M, Takagane A, Nakamura S.

Oncology. 2005;68(4-6):548-57. Epub 2005 Jul 20.

PMID:
16037688
14.

TP53 mutation-mediated genomic instability induces the evolution of chemoresistance and recurrence in epithelial ovarian cancer.

Zhang M, Zhuang G, Sun X, Shen Y, Wang W, Li Q, Di W.

Diagn Pathol. 2017 Feb 2;12(1):16. doi: 10.1186/s13000-017-0605-8.

15.

Tissue aluminum concentration does not affect the genomic stability of ERBB2, C-MYC, and CCND1 genes in breast cancer.

Rodrigues-Peres RM, Cadore S, Febraio S, Heinrich JK, Serra KP, Derchain SF, Vassallo J, Sarian LO.

Biol Trace Elem Res. 2013 Sep;154(3):345-51. doi: 10.1007/s12011-013-9751-3. Epub 2013 Jul 17.

PMID:
23861098
16.

Dysplastic Lipoma: A Distinctive Atypical Lipomatous Neoplasm With Anisocytosis, Focal Nuclear Atypia, p53 Overexpression, and a Lack of MDM2 Gene Amplification by FISH; A Report of 66 Cases Demonstrating Occasional Multifocality and a Rare Association With Retinoblastoma.

Michal M, Agaimy A, Contreras AL, Svajdler M, Kazakov DV, Steiner P, Grossmann P, Martinek P, Hadravsky L, Michalova K, Svajdler P, Szep Z, Michal M, Fetsch JF.

Am J Surg Pathol. 2018 Nov;42(11):1530-1540. doi: 10.1097/PAS.0000000000001129.

PMID:
30001242
17.

Aneuploidy of chromosome 8 as detected by interphase fluorescence in situ hybridization is a recurrent finding in primary and metastatic breast cancer.

Roka S, Fiegl M, Zojer N, Filipits M, Schuster R, Steiner B, Jakesz R, Huber H, Drach J.

Breast Cancer Res Treat. 1998 Mar;48(2):125-33.

PMID:
9596484
18.

MYC is amplified in BRCA1-associated breast cancers.

Grushko TA, Dignam JJ, Das S, Blackwood AM, Perou CM, Ridderstråle KK, Anderson KN, Wei MJ, Adams AJ, Hagos FG, Sveen L, Lynch HT, Weber BL, Olopade OI.

Clin Cancer Res. 2004 Jan 15;10(2):499-507.

20.

Numeric alterations in chromosomes 7 and 8 detected by fluorescent in situ hybridization correlate with high-grade localized prostate cancer.

Barranco MA, Alcaraz A, Corral JM, Solé M, Mallofré C, Llopis J, Rodríguez A, Ribal MJ, Alvarez-Vijande R, Carretero P.

Eur Urol. 1998;34(5):419-25.

PMID:
9803005

Supplemental Content

Support Center